2243718
Cooperative Agreement
Overview
Grant Description
STTR Phase II: Development of a Smart Remote Health Management System for Patients with Kidney Disease - The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to develop a novel technology for the early detection of complications and effective management of kidney disease at home.
More than 37 million patients in the US have chronic kidney disease, which is associated with increased mortality and morbidity, including a greater risk of cardiovascular disease, hospitalization, premature death, and progression to end-stage kidney disease.
According to the Centers for Disease Control and Prevention, in 2018, treating Medicare beneficiaries with chronic kidney disease cost over $81 billion, and approximately 20% of the Medicare budget was spent on kidney disease.
This project leverages a medical device and digital tools with advanced analytics capabilities to provide actionable data and key health insights for timely interventions for at-risk patients.
There is a rapid shift towards value-based healthcare from the traditional fee-for-service model accelerated by the significant cost burden and poor outcomes, especially in kidney care management.
This solution is designed to facilitate this transition seamlessly, lowering unnecessary emergency room visits and/or hospitalizations, and minimizing exacerbations and associated healthcare costs in a disease condition that contributes over $100 billion in healthcare expenses.
This STTR Phase II project develops a comprehensive disease management solution for chronic kidney disease by offering a personalized clinical-decision support system for providers as well as a companion diagnostic solution for patients to improve therapeutic benefits.
There is a dearth of reliable and accurate predictive tools that can non-invasively measure critical biophysical and biochemical markers to inform clinical care and empower self-identification of undesirable effects.
The objective of this research is to develop and validate disruptive technologies for the non-invasive assessment of biomarkers critical to chronic kidney disease diagnosis and management such as hemoglobin levels, electrocardiography (ECG)-based arrhythmia, estimated potassium levels, and lung functions, augmenting the existing capability that measure 10+ vital signs.
The innovation also includes a novel concept for any medical device, to record and broadcast personalized messages in a trusted voice (physician/family member), to improve treatment adherence and outcomes.
The project further incorporates a proprietary cloud-based analytics system that leverages both subjective and objective data to generate a unique "digital fingerprint" for effective management and triage.
Consistent use of the proposed solution will improve symptoms management, care delivery, and diagnosis, and ultimately lead to dramatic reductions in hospitalizations, total medical expenditure related to morbidity and lost productivity, and patient anxiety.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are planned for this award.
More than 37 million patients in the US have chronic kidney disease, which is associated with increased mortality and morbidity, including a greater risk of cardiovascular disease, hospitalization, premature death, and progression to end-stage kidney disease.
According to the Centers for Disease Control and Prevention, in 2018, treating Medicare beneficiaries with chronic kidney disease cost over $81 billion, and approximately 20% of the Medicare budget was spent on kidney disease.
This project leverages a medical device and digital tools with advanced analytics capabilities to provide actionable data and key health insights for timely interventions for at-risk patients.
There is a rapid shift towards value-based healthcare from the traditional fee-for-service model accelerated by the significant cost burden and poor outcomes, especially in kidney care management.
This solution is designed to facilitate this transition seamlessly, lowering unnecessary emergency room visits and/or hospitalizations, and minimizing exacerbations and associated healthcare costs in a disease condition that contributes over $100 billion in healthcare expenses.
This STTR Phase II project develops a comprehensive disease management solution for chronic kidney disease by offering a personalized clinical-decision support system for providers as well as a companion diagnostic solution for patients to improve therapeutic benefits.
There is a dearth of reliable and accurate predictive tools that can non-invasively measure critical biophysical and biochemical markers to inform clinical care and empower self-identification of undesirable effects.
The objective of this research is to develop and validate disruptive technologies for the non-invasive assessment of biomarkers critical to chronic kidney disease diagnosis and management such as hemoglobin levels, electrocardiography (ECG)-based arrhythmia, estimated potassium levels, and lung functions, augmenting the existing capability that measure 10+ vital signs.
The innovation also includes a novel concept for any medical device, to record and broadcast personalized messages in a trusted voice (physician/family member), to improve treatment adherence and outcomes.
The project further incorporates a proprietary cloud-based analytics system that leverages both subjective and objective data to generate a unique "digital fingerprint" for effective management and triage.
Consistent use of the proposed solution will improve symptoms management, care delivery, and diagnosis, and ultimately lead to dramatic reductions in hospitalizations, total medical expenditure related to morbidity and lost productivity, and patient anxiety.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22552
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Baltimore,
Maryland
21231-3030
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-552
Aidar Health was awarded
Cooperative Agreement 2243718
worth $1,000,000
from National Science Foundation in October 2023 with work to be completed primarily in Baltimore Maryland United States.
The grant
has a duration of 2 years and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
STTR Phase II
Title
STTR Phase II:Development of a Smart Remote Health Management System for Patients with Kidney Disease
Abstract
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to develop a novel technology for the early detection of complications and effective management of kidney disease at home. More than 37 million patients in the US have chronic kidney disease, which is associated with increased mortality and morbidity, including a greater risk of cardiovascular disease, hospitalization, premature death, and progression to end-stage kidney disease. According to the Centers for Disease Control and Prevention, in 2018, treating Medicare beneficiaries with chronic kidney disease cost over $81 billion, and approximately 20% of the Medicare budget was spent on kidney disease. This project leverages a medical device and digital tools with advanced analytics capabilities to provide actionable data and key health insights for timely interventions for at-risk patients. There is a rapid shift towards value-based healthcare from the traditional fee-for-service model accelerated by the significant cost burden and poor outcomes, especially in kidney care management. This solution is designed to facilitate this transition seamlessly, lowering unnecessary emergency room visits and/or hospitalizations, and minimizing exacerbations and associated healthcare costs in a disease condition that contributes over $100 billion in healthcare expenses._x000D_ _x000D_ This STTR Phase II project develops a comprehensive disease management solution for chronic kidney disease by offering a personalized clinical-decision support system for providers as well as a companion diagnostic solution for patients to improve therapeutic benefits. There is a dearth of reliable and accurate predictive tools that can non-invasively measure critical biophysical and biochemical markers to inform clinical care and empower self-identification of undesirable effects. The objective of this research is to develop and validate disruptive technologies for the non-invasive assessment of biomarkers critical to chronic kidney disease diagnosis and management such as hemoglobin levels, electrocardiography (ECG)-based arrhythmia, estimated potassium levels, and lung functions, augmenting the existing capability that measure 10+ vital signs. The innovation also includes a novel concept for any medical device, to record and broadcast personalized messages in a trusted voice (physician/family member), to improve treatment adherence and outcomes. The project further incorporates a proprietary cloud-based analytics system that leverages both subjective and objective data to generate a unique ‘digital fingerprint’ for effective management and triage. Consistent use of the proposed solution will improve symptoms management, care delivery, and diagnosis, and ultimately lead to dramatic reductions in hospitalizations, total medical expenditure related to morbidity and lost productivity, and patient anxiety._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
DH
Solicitation Number
NSF 22-552
Status
(Complete)
Last Modified 10/25/23
Period of Performance
10/1/23
Start Date
9/30/25
End Date
Funding Split
$1.0M
Federal Obligation
$0.0
Non-Federal Obligation
$1.0M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2243718
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
JEMYBJLDN1T3
Awardee CAGE
7RWW7
Performance District
MD-07
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $1,000,000 | 100% |
Modified: 10/25/23